NEWSMore +
-
Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
-
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
-
Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer
